57 citations · 62 across the 4 of their papers we have counts for
4 papers
Advance in Reversible Covalent Kinase Inhibitors
Zheng Zhao, Philip E. Bourne
Reversible covalent kinase inhibitors (RCKIs) are a class of novel kinase inhibitors attracting increasing attention because they simultaneously show the selectivity of covalent ki…
Using the structural kinome to systematize kinase drug discovery
Zheng Zhao, Philip E. Bourne
Kinase-targeted drug design is challenging. It requires designing inhibitors that can bind to specific kinases when all kinase catalytic domains share a common folding scaffold tha…
Structural insights into characterizing binding sites in EGFR kinase mutants
Zheng Zhao, Lei Xie, Philip E. Bourne
Over the last two decades epidermal growth factor receptor (EGFR) kinase has become an important target to treat non-small cell lung cancer (NSCLC). Currently, three generations of…
Overview of Current Type I/II Kinase Inhibitors
Zheng Zhao, Philip E. Bourne
Research on kinase-targeting drugs has made great strides over the last 30 years and is attracting greater attention for the treatment of yet more kinase-related diseases. Currentl…